CHMP positive opinion for Triple Combination of CFTR modulators

We are pleased to inform you that the CHMP, the European Committee for Medicinal Products for Human Use, has given a positive opinion for the use of the triple combination […]

 Read more

First site initiation for OligoGpivotalCF in Austria

OligoGpivotalCF is about to start! On 6 May 2020 the first site was initiated in Wels, Austria, and more site initiation visits are planned for the coming months. Pending the […]

 Read more

CF Europe requests that EMA consider a conditional marketing authorisation for the triple combination

In February, we appealed to the EMA to review the latest triple combination modulator therapy, elexacaftor–tezacaftor–ivacaftor, with a sense of urgency. Today, the urgent need for this therapy could not […]

 Read more

Our letter to EMA to support the evaluation of the triple combination of CFTR modulators

On behalf of the 48 national Associations in Europe, representing people with CF and their families, CF Europe has sent a letter to the Chair and the Rapporteurs at EMA […]

 Read more

Contact information

  • Hilde De Keyser
  • 0032 - (0)2 61 32 716
  • Driebruggenstraat 124, 1160 Brussel
  • Chamber of Commerce number: 0640.670.746

Subscribe to newsletter